| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.44 | 30.9% | 1.4% |
| Total Income | 1.44 | 30.9% | 1.4% |
| Expenditure | 1.94 | 3.2% | 1.0% |
| PBT | — | ||
| Net Profit | -6.27 | 42.8% | 40.6% |
| OPM | -34.37% | 36.45pp | 0.06pp |
| NPM | — | ||
| EPS | -2.09 | 0.9% | 35.9% |
Arcadia Biosciences Announces Q2 2026 Financial Results and Business Highlights
14 Aug 2026 · 14 Aug, 1:48 am
Summary
Arcadia Biosciences reported second quarter 2026 revenues of $1.443 million, a 1% decrease year-over-year, and first half revenues of $2.543 million, down 4%. The company experienced a net loss attributable to common stockholders of $6.3 million for the quarter and $10.7 million for the first half. Management highlighted a significant reduction in cash used in operating activities to $319,000 for the quarter and the successful closing of a $4 million private placement, bolstering their cash position to $4.2 million. The company also noted strong recent sales performance for its Zola® product, with July sales exceeding $740,000.
Key Highlights
- 1
Total revenues for the second quarter of 2026 were $1.443 million, a slight decrease of 1% compared to $1.455 million in the same period of 2025.
- 2
For the first half of 2026, total revenues were $2.543 million, down 4% from $2.655 million in the first half of 2025, primarily due to low inventory and shipping delays.
- 3
Net loss attributable to common stockholders for the second quarter of 2026 was $6.3 million, or $2.09 per share, compared to a net loss of $4.5 million, or $3.26 per share, in the prior year's second quarter.
- 4
The first half of 2026 resulted in a net loss attributable to common stockholders of $10.7 million, or $4.19 per share, compared to a net loss of $1.9 million, or $1.36 per share, in the first half of 2025.
- 5
Cash used in operating activities was only $319,000 in the second quarter of 2026.
- 6
Arcadia closed a $4 million private placement in June 2026 and ended the second quarter with $4.2 million in cash.
- 7
July monthly Zola® sales exceeded $740,000 and surpassed $1 million through the first week of August.
Management Comments
T.J. Schaefer
We were very pleased with our second quarter financial results. Our cash used in operating activities was only $319,000 during the quarter, we have a cash balance of $4.2 million at the end of the quarter and our SG&A expenses declined by $1,000,000 versus the same period of last year, to an all-time low. We believe Zola®has reached an inflection point and is now entering a new growth phase. While second quarter sales were flat compared to last year due to low inventory and shipping delays, these issues have been corrected resulting in July sales that were more than half of the sales for the entire second quarter that we are reporting today. In addition, after raising $4 million in gross proceeds through a private placement in June, we now have the cash to fund Zola’s growth, which we expect to accelerate as a result of new products we are bringing to market. In Q4 2026, we will launch a 1-liter espresso with a new formula that tastes more like coffee than coconut water and has pre-launch commitments from our two largest customers. In the first half of 2027, we have a plan to launch three new additional products that we are very excited about.
Informational and educational content only. Not investment advice.